Sesquiterpene lactones isolated from indigenous Middle Eastern plants inhibit tumor promoter-induced transformation of JB6 cells
© Saikali et al.; licensee BioMed Central Ltd. 2012
Received: 12 March 2012
Accepted: 19 June 2012
Published: 9 July 2012
Sesquiterpene lactones (SL) are plant secondary metabolites that are known for their anti-fungal, anti-bacterial, anti-inflammatory, and anti-tumor properties. Considering that several SL-derived drugs are currently in cancer clinical trials, we have tested two SL molecules, 3-β-methoxy-iso-seco-tanapartholide (β-tan) isolated from Achillea falcata and salograviolide A (Sal A) isolated from Centaurea ainetensis, for their anti-tumor properties. We used the mouse epidermal JB6P + cells as a model for tumor promotion and cellular transformation. Key players that are involved in cellular transformation and tumorigenesis are the AP-1 and NF-κB transcription factors; therefore, we assessed how β-tan and Sal A modulate their signaling pathways in JB6P + cells.
The effects of β-tan and Sal A on the growth of normal and neoplastic keratinocytes and on the tumor promotion-responsive JB6P + cells were determined using the MTT assay. Anchorage-independent cell growth transformation assays were used to evaluate the anti-tumor promoting properties of these SL molecules in JB6P + cells and dual luciferase reporter assays and western blot analysis were used to investigate their effects on tumor promoter-induced AP-1 and NF-κB activities and protein levels of key AP-1 and NF-кB target genes.
β-tan and Sal A selectively inhibited tumor promoter-induced cell growth and transformation of JB6P + cells at concentrations that do not affect JB6P + and primary keratinocytes basal cell growth. In addition, both molecules reduced basal and tumor promoter-induced NF-κB transcriptional activities, differentially regulated basal and tumor promoter-induced AP-1 transcriptional activities, and modulated key players of the AP-1 and NF-κB signaling pathways.
These results highlight the anti-tumor promoting properties of β-tan and Sal A. These SL molecules isolated from two plant species native to the Middle East may provide opportunities for complementary medicine practices.
There is a renewed interest in the use of natural compounds to prevent/treat several types of diseases including cancer and inflammatory conditions [1, 2]. Currently, there are more than 200 natural product-derived drugs already in preclinical/clinical development or in the clinic [1, 3, 4]. The therapeutic properties of medicinal plants are generally attributed to plant secondary metabolites, an example of which are sesquiterpene lactones (SL), which are present almost exclusively in plant species belonging to the family Asteraceae[5, 6]. This family comprises plant species commonly used in ethnomedicine , some of which have been reported to specifically treat diseases such as cancer, inflammation, headaches, and infections [6, 8]. Sesquiterpene lactones often colorless and with a bitter taste, are a stable form of terpenoids and are divided into four groups: germacranolides, eudesmanolides, guaianolides, and pseudoguaianolides . The bioactivity of a SL molecule has been attributed to several factors including the number of alkylating centers, the lipophilicity of the molecule, and its geometry . Importantly, several SL-derived drugs are currently being tested in cancer clinical trials .
Following bioassay guided fractionation, we have isolated, identified, and characterized two SL molecules of the guaianolide group, 3-β-methoxy-iso-seco-tanapartholide (β-tan) and salograviolide A (Sal A), with promising anti-tumor and anti-inflammatory activities [10–14].
β-tan which was purified from Achillea falcata, a species native to Lebanon and the Middle East , differentially inhibited the growth of the epidermal human HaCaT cells at non-cytotoxic concentrations to primary epidermal keratinocytes . Sal A, which was isolated from Centaurea ainetensis, also a species native to Lebanon and the Middle East, was found to possess anti-inflammatory [13, 14, 16] and anti-cancer activities in a mouse colon cancer model and in skin cancer cells at different stages of tumorigenesis [10, 12, 17].
In this study, we specifically investigated whether these SL molecules target the tumor promotion stage of tumorigenesis and cell transformation using the well-established JB6 mouse epidermal cell system, which includes the promotion-sensitive P + cells [18, 19]. In contrast to tumor initiation, tumor promotion is largely reversible, dependent on epigenetic mechanisms, and is a rate-limiting step in multi-stage carcinogenesis, making it an attractive target for anticancer drugs [20, 21]. The JB6P + cells can be transformed to malignancy by tumor promoters, and hence, constitute an ideal model to identify anti-tumor promoting and chemopreventive agents and to decipher their mechanism of action [19, 22–24].
The anti-tumor promoting activities of β-tan and Sal A and their modulation of AP-1 and NF-κB signaling were investigated using JB6P + cells. AP-1 and NF-κB signaling pathways have been shown to be up regulated and to play key roles in tumor promotion and epidermal tumorigenesis [19, 25]. Members of the AP-1 and NF-κB complexes are expressed at high levels in JB6P + cells , and AP-1 and NF-κB activities are required for tumor promotion [26, 27]. The inhibition of NF-κB and/or AP-1 activities abrogates transformation in JB6 cells in transgenic mice and in human keratinocytes [25, 28–30].
Cells and culture conditions
Primary mouse keratinocytes (PMKs) were freshly prepared from one- to-two day-old neonatal BALB-c mice as described by Yuspa et al.. The SP-1 benign tumor cell lines were produced in SENCAR mice . The neoplastic PAM212 cell line is a differentiated squamous cell carcinoma (SCC) that spontaneously transformed in vitro. I7 is a spindle cell line derived from a skin carcinoma formed from PMKs infected with the v-rasHa and c-fos oncogenes and grafted to nude mice . PAM212, SP1, and I7 cell lines were generously provided by Dr. Stuart H. Yuspa (NIH, Bethesda, MD). The JB6P + cell line is a tumor promoter-sensitive clonal variant (clone 41, subclone 5a), derived from the JB6 model for tumor promotion, and originally derived from primary mouse epidermal cells . The JB6P + cell line was generously provided by Dr. Nancy Colburn (NCI, Frederick, MD).
SP1, PAM212, and PMK cells were cultured in fresh Eagle Minimum Essential Medium (EMEM) (Bio Whittaker, Cambrex Co., MD) containing 10% chelated fetal bovine serum (FBS) with no more than 0.05 mM Ca++ to maintain a basal proliferating cell phenotype , 1% L-glutamine, and 1% penicillin-streptomysin antibiotics (Gibco-BRL Life Technologies, Carlsbad, CA). I7 cells were cultured in complete EMEM medium with 10% FBS, 2 mM L-glutamine, and 1% penicillin-streptomysin. JB6P + cells were cultured in EMEM (SIGMA, M2279) containing 4% heat inactivated FBS (Gibco BRL Life), 2 mM L-glutamine, 25 μ g/mL of gentamicin (SIGMA SG 1397 M10) and 1% non-essential amino acids (NEAA) (Gibco). JB6P + cells were used up to ten passages in culture to avoid spontaneous transformation in vitro. All cells were grown in a humidified incubator which was set at 95% air and 5% CO2 except for PMKs which were grown in 93% air and 7% CO2.
Sesquiterpene lactones isolation and cell treatments
Extraction, purification, and identification of the SL β-tan and Sal A from Achillea falcata and Centaurea ainetensis, respectively, were performed as previously described [11, 14]. Briefly, the plant material was soaked in methanol and then subjected to filtration and several fractionation steps where the different fractions were subjected to bio-guided fractionation. The sub-fractions with the most potent anti-proliferative activities were further purified, and the pure bioactive compounds, Sal A from Centaurea ainetensis and β-tan from Achillea falcata were identified using 1 H and 13 C NMR identified using several spectroscopic techniques including 1D and 2D NMR as well as mass spectrometry, UV, and IR. β-tan and Sal A were prepared from a stock of 20 mg/ml diluted in absolute ethanol. Cells were treated with the indicated concentrations of β-tan and Sal A. For the control conditions, concentrations of ethanol in culture medium did not exceed 0.1% which had no effect on the growth of cells (data not shown).
Cell growth assay
Cell growth was assayed at indicated time points using the MTT Cell Proliferation Kit according to manufacturer’s instructions (Roche Diagnostics). The proliferation assay is an MTT-based method which measures the ability of metabolically active cells to convert tetrazolium salt into a blue formazan product, the absorbance of which is recorded at 595 nm using an ELISA microplate reader. Cell growth results were expressed as percentage of control and were derived from the mean of triplicate wells.
Cells were seeded in 96-well plates, at a density of 1 x 105 cells/ml in 100 μl media, and incubated until confluency reached 50%. After which the media was removed and 100 μl of fresh media containing different concentrations of β-tan or Sal A were placed for treatment conditions, or a maximum of 0.1% ethanol in media for control conditions. For MTT assays using the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) (Enzo Life Sciences, USA), JB6P + cells were treated with either 5 nM TPA  in media only, or with the indicated concentrations of β-tan or Sal A with or without 5 nM TPA co-treatment.
Anchorage-independent growth transformation assay
Colony growth in soft agar is a well-established index of cell transformation . Anchorage-independent growth was studied using the CytoSelectTM 96-Well Cell Transformation Assay kit (Cell Biolabs) according to manufacturer’s instructions. The base agar layer (0.6% agar, 10% FBS, 2 mM L-glutamine and 25 μg/ml gentamicin) was layered into wells of a 96-well plate and allowed to solidify. Once solidified, the cell agar layer containing 0.4% agar with JB6P + cells treated with the indicated concentrations of β-tan and Sal A, with 5 nM TPA [23, 35, 36], in complete EMEM (10% FBS), was layered on top of the base agar layer. The indicated concentrations of β-tan and Sal A were then prepared in complete EMEM (10% FBS), with 5 nM TPA and placed over the solidified cell agar layer. The cells were incubated for 9 ± 1 day at 37°C and 5% CO2, replenished with the indicated concentrations of β-tan and Sal A with 5 nM TPA every 3 days. Colonies were photographed and then quantified using the CyQuant GR Dye where the fluorescence was measured using a 96-well fluorometer set at a 485/520 nm filter set.
Dual luciferase reporter assay for AP-1 and NF-κB transcriptional activities
JB6P + cells were seeded in 24-well plates (1 x 105 cells/ml), and at 60–80% confluency, cells were co-transfected with the AP-1 (pXP2-35alb-Luc, 0.8 μg) or NF-κB (pGL2-IL-6–Luc, 0.8 μg) firefly luciferase reporter plasmids with the renilla luciferase reporter plasmid (pRL-SV40, 0.04 μg). The pXP2-35alb-Luc harbors the albumin promoter upstream from the luciferase gene. Within this promoter, the GCN4 oligo sequence, which harbors the AP-1 binding site, was ligated. The pGL2-IL-6–Luc uses the IL-6 promoter region containing four putative NF-κB binding sites. These reporter plasmids were kindly provided by Dr. Nancy Colburn (NCI). Co-transfection was done using LipofectamineTM 2000 with PLUSTM reagent (Invitrogen), without antibiotics for 3 h at 37°C, 5% CO2, then replenished with complete EMEM (4% heat-inactivated FBS, with antibiotics) for at least 12 h. Cells were then treated with the indicated concentrations of β-tan and Sal A, with or without 16 nM TPA for 24 h as described . Cell lysates were then prepared and luminescence measured using the Dual Luciferase Reporter Assay Kit (Promega) as per manufacturer’s instructions. The firefly reporter transfection efficiencies were normalized relative to the renilla luciferase activity generated by this vector and plotted as percentage of control.
Western blot analysis
JB6P + cells were plated in 100 mm dishes at a density of 50,000 cells/ml. At 80–90% confluency, cells were starved with 0.1% FBS for 24 h, then were pre-treated with either 10 μg/ml β-tan or 15 μg/ml Sal A for 1 hr followed by 15 min or 6 h 32 nM TPA [35, 37]. Whole cell protein extracts (30 μg) were prepared as described  and probed overnight at +4 °C with primary antibodies against MMP-9 (Chemicon, Millipore) MMP-2 (Chemicon, Millipore), GAPDH, IκBα, cyclin D1, p16, Bax and Bcl-2 (Santa Cruz Biotechnology, Inc.) followed by secondary antibodies conjugated with horseradish peroxidase. Equal protein loading and quality were verified through GAPDH reprobing and Ponceau staining of membranes. The immunocomplexes were visualized using enhanced chemiluminescent kits obtained from Santa Cruz (ECL system). Bands were quantified using ImageQuant software and the Molecular Dynamics 860 System (Molecular Dynamics, Sunnyvale, CA). In some western blots, adjustments of brightness and contrast were applied to all bands of the same membrane image.
Data presented are the means ± SE of at least two independent experiments or as indicated. Significant differences were determined using the post-hoc tests; Tukey, SNK and Dunnett tests of the SPSS Version 16.0 software. Significance was set at indicated p-values (0.05, 0.01 or 0.001).
β-tan and Sal A selectively inhibit the growth of tumor cells
β-tan and Sal A inhibit tumor promoter-induced proliferation and transformation of JB6P + cells
Treatment with Sal A at 5 μg/ml had no growth inhibitory effect in JB6P + cells while this concentration caused a significant inhibition of TPA-induced proliferation by 33 ± 20% relative to the TPA-treated cells (p < 0.001) (Figure 3A). Higher concentrations of Sal A at 10 or 15 μg/ml caused a significant 63 ± 3% and 65 ± 1% decrease in cell proliferation, respectively, with or without the presence of TPA (p < 0.001) (Figure 3A). These results indicate that both SL molecules reduced tumor promoter-induced proliferation of JB6P + cells at concentrations that did not affect the growth of normal cells.
To test whether these two SL molecules inhibit tumor promoter-induced cell transformation, we determined their effects on anchorage-independent cell growth in soft agar, which is a hallmark of malignant transformation. In the presence of tumor promoters, the immortalized but non-tumorigenic JB6P + cells become tumorigenic, forming colonies in an anchorage-independent manner . JB6P + cells treated with only TPA, but not solvent control, exhibit colony growth in soft agar (Figure 3B, C). Importantly, upon co-treatment of β-tan or Sal A with TPA, colony formation was inhibited in a concentration-dependent manner in JB6P + cells (Figure 3B, C). At 0.25 μg/ml, neither β-tan nor Sal A decreased JB6P + colony growth 9 ± 1 day after seeding; however, at 2.5 μg/ml concentrations, which were non-cytotoxic to normal and JB6P + cells by MTT (Figure 2), β-tan and Sal A significantly inhibited tumor promoter-induced colony formation by 66 ± 8% and 51 ± 8%, respectively (p < 0.001) (Figure 3B, C). Both SL molecules completely abrogated colony growth 9 ± 1 day post-seeding at 5 μg/ml concentrations. These results show that β-tan and Sal A inhibit tumor promoter-induced JB6P + cell transformation.
β-tan and Sal A differentially modulate TPA-induced NF-κB and AP-1 activities in JB6P + cells
Elevated levels of AP-1 and NF-κB activities are hallmarks of malignant transformation [19, 27, 37]. Since β-tan and Sal A both inhibited tumor promoter-induced cell transformation, we hypothesized that these SL molecules mediate their anti-tumor promoting activities by repressing AP-1, NF-κB, or both transcriptional activities.
Sal A (5 μg/ml) did not modulate basal AP-1 activity, but caused a non-statistically significant decrease in TPA-induced AP-1 activity. Interestingly, Sal A significantly decreased basal and TPA-induced NF-κB transcriptional activities at 24 h by 37 ± 6% and 54 ± 5%, respectively (p < 0.01) (Figure 4B). Our experiments show that both β-tan and Sal A decreased basal and tumor promoter-induced NF-κB activities, which in fact is a characteristic property of SL .
β-tan and Sal A modulate key target genes of the AP-1 and NF-κB signaling pathways in JB6P + cells
Since both SL molecules inhibited TPA-induced NF-κB transactivation, we next studied their effects on the NF-κB inhibitor, IκBα. Treatment with TPA alone abrogated IκBα protein levels as early as 15 minutes (Figure 5). Interestingly, only pre-treatment with β-tan restored IκBα protein levels after 15 minutes of TPA-treatment. These results indicate that pretreatment with β-tan or Sal A regulate TPA-induced AP-1 and NF-кB target genes that are involved in the regulation of cell growth, cell migration, and metastasis.
In this study, we investigated the anti-tumor promoting effects of β-tan and Sal A, isolated from Achillea falcata and Centaurea ainetensis, respectively, using the JB6 epidermal cell model of tumor promotion and cell transformation. In the multi-stage model of carcinogenesis, the tumor promotion phase is a rate limiting step that is responsible for the clonal expansion of initiated cells and is largely reversible , offering a practical approach for identifying potential inhibitors of cancer development .
Herein, we report that treatment with either Sal A or β-tan preferentially inhibited the growth of murine neoplastic keratinocytes, whilst sparing normal cells. The promotion-sensitive JB6P + cells were the most sensitive to β-tan treatment at concentrations that did not affect the growth of PMKs. Treatment with Sal A was relatively less potent on JB6P + cells, compared to β-tan, where 10 μg/ml β-tan inhibited cell growth by 74 ± 7%, whereas 10 μg/ml Sal A inhibited by 51 ± 4%. Although both belong to the SL guaianolide family, it seems that β-tan, with its relatively open ring structure, possesses higher flexibility, possibly enhancing β-tan diffusion across the cell membrane; in contrast to Sal A which bears a closed ring structure (Figure 1). In addition to the bioactive –α-methylene-γ-lactone ring present in Sal A and β-tan, the latter harbors an additional alkylating center, the cyclopentenone. Moreover, the presence of two hydroxyl (OH) groups within Sal A renders the molecule less lipophilic, possibly decreasing cell membrane penetration and may explain its reduced toxicity to JB6P + cells compared to β-tan.
In studying the anti-tumor promoting properties of these two purified SL molecules, it was essential to assess their effect on TPA-induced JB6P + cell transformation. In this study, we found that both β-tan and Sal A inhibited TPA-induced JB6P + cell transformation, at concentrations not cytotoxic to normal nor to the non-tumorigenic JB6P + cells. A hallmark of cell transformation is the ability of malignant cells to grow in soft agar in an anchorage-independent manner [18, 23, 36]. Our results show that β-tan and Sal A, at concentrations that did not inhibit JB6P + cell proliferation, were effective in reducing TPA-induced proliferation and inhibiting TPA-induced colony formation. These results suggest that β-tan and Sal A may have promising chemopreventive properties in epidermal carcinogenesis. Future in vivo experiments are required to confirm the chemopreventive properties of these purified SL molecules. However, a limiting step for in vivo studies will be the availability of large quantities of these molecules.
The activation of the transcription factors AP-1 and NF-κB is essential for tumor promotion and neoplastic transformation, and are highly expressed in the promoter-sensitive JB6P + cells, and the inhibition of both or either one of these signaling pathways is sufficient to inhibit neoplastic transformation [19, 23, 25]. To study the modulation of tumor promoter-induced AP-1 and NF-κB transcriptional activities by β-tan and Sal A in JB6P + cells, concentrations that inhibited JB6P + cell transformation and did not affect normal cell growth were used. Interestingly, both SL molecules decreased basal and TPA-induced NF-κB activities, but not of TPA-induced AP-1 activity. This suggests that β-tan and Sal A primarily inhibit NF-κB signaling in tumor cells. In fact, it is well established that NF-κB is a vital molecular target for various SL, and some of them, such as parthenolide, artimisinin and thapsigargin are currently in cancer clinical trials [6, 9, 43]. This can be attributed to the presence of the α-methylene-γ-lactone functional group, which directly alkylates cysteine residues of the p65 subunit, interfering with DNA binding [6, 44]. In fact, elevated NF-κB signaling is sufficient to induce epidermal tumor transformation . This prompted us to study the effect of these SL molecules on the protein levels of one of the main NF-κB inhibitors, IκBα. Previous studies have shown that the expression of non-degradable mutants of IκBα and antisense RNA inhibition of NF-κB, result in tumor regression [29, 45–47]. Interestingly, only pre-treatment with β-tan restored IκBα protein levels after 15 minutes of TPA-treatment, suggesting that Sal A and β-tan differentially mediate their inhibition of NF-κB signaling. This differential regulation of IκBα proteins by the SL molecules can be attributed to their differences in alkylating centers and lipophilicity, thus, affecting their interaction with the IκBα proteins. Nevertheless, β-tan also significantly increased basal AP-1 levels in JB6P + cells at concentrations that decreased cell growth. This may implicate the dual role of AP-1 in increased cell proliferation and cell death .
Since earlier studies have shown that AP-1 and NF-κB can interact together , we assessed how both SL molecules modulated key downstream target genes, containing TPA response elements (TREs) common to both AP-1 and NF-κB. Metalloproteinases are essential for tumor promotion, progression, and invasion and AP-1 and NF-κB play a dominant role in the transcriptional activation of the majority of MMPs [50, 51] including MMP-9 and MMP-2. In fact, it was shown in mice lacking MMP-9 that this gene is functionally involved in the regulation of oncogene-induced keratinocyte hyperproliferation, progression to invasive cancer, and end-stage malignant grade epithelial carcinomas . Treatment of TPA-promoted JB6P + cells with β-tan or Sal A, abrogated MMP-9, but not MMP-2, protein levels. This implies that the two SL molecules differentially modulate MMP protein levels suggesting the regulation of MMP2 by factors other than AP-1 and NF-κB.
Another important AP-1 and NF-κB target gene is the CDKI p16. Both SL molecules noticeably up regulated p16 that was reduced upon TPA treatment, which suggests that β-tan and Sal A inhibit cell cycle progression that is induced by tumor promoters. Furthermore, AP-1 and NF-κB components also regulate apoptotic proteins such as the pro-apoptotic Bax and the anti-apoptotic Bcl-2 proteins [38, 51]. SL are known to be inducers of apoptosis in a variety of cancer cells, and this is considered one of the important mechanisms by which SL exert their anti-tumor properties . Our results show that both β-tan and Sal A increase the Bax:Bcl-2 ratios in TPA-promoted JB6P + cells and suggest that Bcl-2 family members are involved in the growth suppressive effects of β-tan and Sal A.
This is the first report which investigates the anti-tumor promoting effects of the SL β-tan and Sal A in cell transformation. Our studies highlight the mechanism by which these SL molecules inhibit tumor promotion by reducing TPA-induced NF-κB activity and in regulating several downstream players involved in cell cycle progression, apoptosis, and tumor invasion. It is well established that tumor promotion is epigenetically regulated, and numerous plant-derived anti-cancer drugs are modulators of epigenetic processes , therefore it would be interesting to test whether these purified SL molecules are epigenetic regulators. Finally, future studies investigating the anti-tumor promoting properties in vivo are needed to test the potential chemopreventive use of these SL molecules.
Cyclin dependent kinase inhibitor
Epidermal growth factor
Eagle’s minimum essential medium
Fetal bovine serum
Inhibitor of NF-κB
Non-essential amino acids
Nuclear magnetic resonance
Primary mouse keratinocytes
- Sal A:
Standard error of mean
Tumor necrosis factor α
TPA response elements.
This work was supported by the Middle East Science Fund (MESF, Jordan). We thank Dr. Stuart Yuspa for supplying the SP-1, PAM 212 and I7 cell lines; Dr. Nancy Colburn for supplying the JB6P + cells, AP-1 (pXP2-35alb-Luc) and NF-κB (pGL2-IL-6–Luc) plasmids; Dr. Marwan El Sabban for the MMP-9 and MMP-2 antibodies; Dr. Rihab Nasr and Dr. Hala Mohtaseb for their valuable suggestions; Dr. Fadia Homeidan for her critical review of the manuscript; and Kamal A. Shair Central Research Science Laboratory at the American University of Beirut, Lebanon.
- Harvey AL: Natural products in drug discovery. Drug Discovery Today. 2008, 13: 894-901. 10.1016/j.drudis.2008.07.004.View ArticlePubMedGoogle Scholar
- Shah B, Seth A, Maheshwari K: A review on medicinal plants as a source of anti-inflammatory agents. Journal of Medicinal Plants Research. 2011, 5: 101-115.View ArticleGoogle Scholar
- Darwiche N, El-Banna S, Gali-Muhtasib H: Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development. Expert Opinion on Drug Discovery. 2007, 2: 361-379. 10.1517/174604220.127.116.111.View ArticlePubMedGoogle Scholar
- Traditional Medicine Fact Sheet No. 134. 2008,http://www.who.int/mediacentre/factsheets/fs134/en/,
- Merfort I: Perspectives on sesquiterpene lactones in inflammation and cancer. Current Drug Targets. 2011, 12: 1560-73. 10.2174/138945011798109437.View ArticlePubMedGoogle Scholar
- Zhang S, Won YK, Ong CN, Shen HM: Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Current Medicinal Chemistry-Anti-Cancer Agents. 2005, 5: 239-249. 10.2174/1568011053765976.View ArticlePubMedGoogle Scholar
- Kaij-a-Kamb M, Amoros M, Girre L: Search for new antiviral agents of plant origin. Pharmaceutica acta Helvetiae. 1992, 67: 130-147.PubMedGoogle Scholar
- Gurib-Fakim A: Medicinal plants: traditions of yesterday and drugs of tomorrow. Molecular aspects of Medicine. 2006, 27: 1-93. 10.1016/j.mam.2005.07.008.View ArticlePubMedGoogle Scholar
- Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA, Darwiche N: What made sesquiterpene lactones reach cancer clinical trials?. Drug Discovery Today. 2010, 15: 668-678. 10.1016/j.drudis.2010.06.002.View ArticlePubMedGoogle Scholar
- Ghantous A, Tayyoun AA, Lteif GA, Saliba NA, Gali-Muhtasib H, El-Sabban M, Darwiche N: Purified Salograviolide A isolated from Centaurea ainetensis causes growth inhibition and apoptosis in neoplastic epidermal cells. International Journal of Oncology. 2008, 32: 841-849.PubMedGoogle Scholar
- Ghantous A, Nasser N, Saab I, Darwiche N, Saliba NA: Structure–activity relationship of seco-tanapartholides isolated from Achillea falcata for inhibition of HaCaT cell growth. European Journal of Medicinal Chemistry. 2009, 44: 3794-3797. 10.1016/j.ejmech.2009.04.029.View ArticlePubMedGoogle Scholar
- El-Najjar N, Dakdouki S, Darwiche N, El-Sabban M, Saliba NA, Gali-Muhtasib H: Anti-colon cancer effects of Salograviolide A isolated from Centaurea ainetensis. Oncology Reports. 2008, 19: 897-904.PubMedGoogle Scholar
- Talhouk RS, El-Jouni1 W, Baalbaki R, Gali-Muhtasib H, Kogan J, Talhouk S: Anti-inflammatory bio-activities in water extract of Centaurea ainetensis. Journal of Medicinal Plants Research. 2008, 2: 024-033.Google Scholar
- Saliba NA, Dakdouki S, Homeidan F, Kogan J, Bouhadir K, Talhouk S, Talhouk R: Bio-guided identification of an anti-inflammatory guaianolide from Centaurea ainetensis. Pharmaceutical Biology. 2009, 47: 701-707. 10.1080/13880200902933021.View ArticleGoogle Scholar
- Nehmé M: Wild flowers of Lebanon. 1977, National Council for Scientific Research, Beirut, NCSR Beirut (Lebanon)Google Scholar
- Al-Saghir J, Al-Ashi R, Salloum R, Saliba NA, Talhouk RS, Homaidan FR: Anti-inflammatory properties of Salograviolide A purified from Lebanese plant Centaurea ainetensis. BMC Complementary and Alternative Medicine. 2009, 9: 36-10.1186/1472-6882-9-36.View ArticlePubMedPubMed CentralGoogle Scholar
- Gali-Muhtasib H, Fakhoury I: Salograviolide A: A Plant-Derived Sesquiterpene Lactone with Promising Anti-Inflammatory and Anticancer Effects. Advances in Cancer Therapy. Edited by: Gali-Muhtasib H. 2011, InTech, 388, 369-388.View ArticleGoogle Scholar
- Colburn NH, Former BF, Nelson KA, Yuspa SH: Tumour promoter induces anchorage independence irreversibly. Nature. 1979, 281: 589-591. 10.1038/281589a0.View ArticlePubMedGoogle Scholar
- Dhar A, Young MR, Colburn NH: The role of AP-1, NF-kappaB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive. Molecular and Cellular Biochemistry. 2002, 234–235: 185-193.View ArticlePubMedGoogle Scholar
- Huang J, Plass C, Gerhäuser C: Cancer chemoprevention by targeting the epigenome. Current Drug Targets. 2010, 12: 1925-1956.View ArticleGoogle Scholar
- Huang YW, Kuo CT, Stoner K, Huang TH, Wang LS: An overview of epigenetics and chemoprevention. FEBS Lett. 2011, 585: 2129-2136. 10.1016/j.febslet.2010.11.002.View ArticlePubMedGoogle Scholar
- Colburn NH: Tumor promoter produces anchorage independence in mouse epidermal cells by an induction mechanism. Carcinogenesis. 1980, 1: 951-954. 10.1093/carcin/1.11.951.View ArticlePubMedGoogle Scholar
- Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH: Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proceedings of the National Academy of Sciences. 1994, 91: 609-613. 10.1073/pnas.91.2.609.View ArticleGoogle Scholar
- Weber TJ, Siegel RW, Markillie LM, Chrisler WB, Lei XC, Colburn NH: A paracrine signal mediates the cell transformation response to low dose gamma radiation in JB6 cells. Molecular Carcinogenesis. 2005, 43: 31-37. 10.1002/mc.20092.View ArticlePubMedGoogle Scholar
- Li JJ, Westergaard C, Ghosh P, Colburn NH: Inhibitors of both nuclear factor-κB and activator protein-1 activation block the neoplastic transformation response. Cancer Research. 1997, 57: 3569-3576.PubMedGoogle Scholar
- Young MR, Li JJ, Rincón M, Flavell RA, Sathyanarayana BK, Hunziker R, Colburn NH: Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proceedings of the National Academy of Sciences. 1999, 96: 9827-9832. 10.1073/pnas.96.17.9827.View ArticleGoogle Scholar
- Hsu TC, Nair R, Tulsian P, Camalier CE, Hegamyer GA, Young MR, Colburn NH: Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-κB activation. Cancer Research. 2001, 61: 4160-4168.PubMedGoogle Scholar
- Watts RG, Huang C, Young MR, Li JJ, Dong Z, Pennie WD, Colburn NH: Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene. 1998, 17: 3493-3498.View ArticlePubMedGoogle Scholar
- Hsu TC, Young MR, Cmarik J, Colburn NH: Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis. Free Radical Biology and Medicine. 2000, 28: 1338-1348. 10.1016/S0891-5849(00)00220-3.View ArticlePubMedGoogle Scholar
- Young MR, Yang HS, Colburn NH: Promising molecular targets for cancer prevention: AP-1, NF-[kappa] B and Pdcd4. Trends in Molecular Medicine. 2003, 9: 36-41. 10.1016/S1471-4914(02)00009-6.View ArticlePubMedGoogle Scholar
- Yuspa SH, Koehler B, Kulesz-Martin M, Hennings H: Clonal growth of mouse epidermal cells in medium with reduced calcium concentration. Journal of Investigative Dermatology. 1981, 76: 144-146. 10.1111/1523-1747.ep12525490.View ArticlePubMedGoogle Scholar
- Greenhalgh DA, Welty DJ, Player A, Yuspa SH: Two oncogenes, v-fos and v-ras, cooperate to convert normal keratinocytes to squamous cell carcinoma. Proceedings of the National Academy of Sciences. 1990, 87: 643-647. 10.1073/pnas.87.2.643.View ArticleGoogle Scholar
- Colburn NH, Wendel EJ, Abruzzo G: Dissociation of mitogenesis and late-stage promotion of tumor cell phenotype by phorbol esters: mitogen-resistant variants are sensitive to promotion. Proceedings of the National Academy of Sciences. 1981, 78: 6912-6916. 10.1073/pnas.78.11.6912.View ArticleGoogle Scholar
- Yuspa SH, Kilkenny AE, Steinert PM, Roop DR: Expression of murine epidermal differentiation markers is tightly regulated by restricted extracellular calcium concentrations in vitro. The Journal of Cell Biology. 1989, 109: 1207-1217. 10.1083/jcb.109.3.1207.View ArticlePubMedGoogle Scholar
- Suzukawa K, Weber TJ, Colburn NH: AP-1, NF-kappa-B, and ERK activation thresholds for promotion of neoplastic transformation in the mouse epidermal JB6 model. Environmental Health Perspectives. 2002, 110: 865-870.View ArticlePubMedPubMed CentralGoogle Scholar
- Dong Z, Cmarik JL, Wendel EJ, Colburn NH: Differential transformation efficiency but not AP-1 induction under anchorage-dependent and-independent conditions. Carcinogenesis. 1994, 15: 1001-1004. 10.1093/carcin/15.5.1001.View ArticlePubMedGoogle Scholar
- Lee KW, Kang NJ, Heo YS, Rogozin EA, Pugliese A, Hwang MK, Bowden GT, Bode AM, Lee HJ, Dong Z: Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Research. 2008, 68: 946-955. 10.1158/0008-5472.CAN-07-3140.View ArticlePubMedPubMed CentralGoogle Scholar
- Eferl R, Wagner EF: AP-1: a double-edged sword in tumorigenesis. Nature Reviews Cancer. 2003, 3: 859-868. 10.1038/nrc1209.View ArticlePubMedGoogle Scholar
- Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999, 18: 6853-6866. 10.1038/sj.onc.1203239.View ArticlePubMedGoogle Scholar
- Plati J, Bucur O, Khosravi-Far R: Apoptotic cell signaling in cancer progression and therapy. Integative Biology. 2011, 3: 279-296. 10.1039/c0ib00144a.View ArticleGoogle Scholar
- Hennings H, Shores R, Wenk ML, Spangler EF, Tarone R, Yuspa SH: Malignant conversion of mouse skin tumours is increased by tumour initiators and unaffected by tumour promoters. Nature. 1983, 304: 67-69. 10.1038/304067a0.View ArticlePubMedGoogle Scholar
- Ding M, Feng R, Wang SY, Bowman L, Lu Y, Qian Y, Castranova V, Jiang BH, Shi X: Cyanidin-3-glucoside, a natural product derived from blackberry, exhibits chemopreventive and chemotherapeutic activity. Journal of Biological Chemistry. 2006, 281: 17359-17368. 10.1074/jbc.M600861200.View ArticlePubMedGoogle Scholar
- Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V, Schulze-Osthoff K, Dröge W, Schmitz ML: Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. Journal of Biological Chemistry. 1998, 273: 1288-1297. 10.1074/jbc.273.3.1288.View ArticlePubMedGoogle Scholar
- Garcia-Pineres AJ, Castro V, Mora G, Schmidt TJ, Strunck E, Pahl HL, Merfort I: Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. Journal of Biological Chemistry. 2001, 276: 39713-39720. 10.1074/jbc.M101985200.View ArticlePubMedGoogle Scholar
- Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 1996, 274: 787-789. 10.1126/science.274.5288.787.View ArticlePubMedGoogle Scholar
- Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin AS: Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation. Journal of Biological Chemistry. 1997, 272: 24113-24116. 10.1074/jbc.272.39.24113.View ArticlePubMedGoogle Scholar
- Latimer M, Ernst MK, Dunn LL, Drutskaya M, Rice NR: The N-Terminal Domain of I kappa B alpha Masks the Nuclear Localization Signal (s) of p50 and c-Rel Homodimers. Molecular and Cellular Biology. 1998, 18: 2640-2649.View ArticlePubMedPubMed CentralGoogle Scholar
- Shaulian E, Karin M: AP-1 as a regulator of cell life and death. Nature Cell Biology. 2002, 4: E131-E136. 10.1038/ncb0502-e131.View ArticlePubMedGoogle Scholar
- Stein B, Baldwin AS, Ballard DW, Greene WC, Angel P, Herrlich P: Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. The EMBO journal. 1993, 12: 3879-3891.PubMedPubMed CentralGoogle Scholar
- Angel P, Szabowski A, Schorpp-Kistner M: Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene. 2001, 20: 2413-2423. 10.1038/sj.onc.1204380.View ArticlePubMedGoogle Scholar
- Karin M, Lin A: NF-kappaB at the crossroads of life and death. Nature Immunology. 2002, 3: 221-227.View ArticlePubMedGoogle Scholar
- Coussens LM, Tinkle CL, Hanahan D, Werb Z: MMP-9 supplied by bone marrow–derived cells contributes to skin carcinogenesis. Cell. 2000, 103: 481-490. 10.1016/S0092-8674(00)00139-2.View ArticlePubMedPubMed CentralGoogle Scholar
- Schneider-Stock R, Ghantous A, Bajbouj K, Saikali M, Darwiche N: Epigenetic mechanisms of plant-derived anticancer drugs. Frontiers in Bioscience. 2012, 17: 129-173. 10.2741/3919.View ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/12/89/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.